Milk antibody response after 3rd COVID-19 vaccine and SARS-CoV-2 infection and implications for infant protection
Yarden Golan(Cornell University), Mary Prahl(University of California, San Francisco), Soumya Hunagund(University of California, San Francisco), Valerie J. Flaherman(University of California, San Francisco), Ifeyinwa V. Asiodu(Health Care Foundation), Christine Y. Lin(Society for Maternal-Fetal Medicine), Yusuke Matsui(Gladstone Institutes), Arianna G. Cassidy(University of California, San Francisco), Nida Özarslan(Society for Maternal-Fetal Medicine), Mikias Ilala, Nadav Ahituv(University of California, San Francisco), Lin Li(Kunming Medical University), Unurzul Jigmeddagva(Reproductive Science Center), Stephanie L. Gaw(University of California, San Francisco), Caryl Gay(University of California, San Francisco)
Cited by 11
Related Papers
Update: Interim Guidance for the Diagnosis, Evaluation, and Management of Infants with Possible Congenital Zika Virus Infection — United States, October 2017
|MMWR Morbidity and Mortality Weekly Report|2017|218
Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity
|Science Translational Medicine|2022|139
Circulating Angiogenic Factor Levels in Hypertensive Disorders of Pregnancy
|NEJM Evidence|2022|130
Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses
|Science Translational Medicine|2022|125